A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Study summary

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986488 and Adagrasib

Plus 2 other study approaches.

Who it may be forAdvanced Malignant Tumors

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 29, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Bristol-Myers Squibb
Interventions being studied: Drug: BMS-986488; Drug: Adagrasib; Drug: Cetuximab; Drug: Nivolumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Immunotherapy→Targeted therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participant must be ≥ 18 years of age.
Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Parts 2A, 1D, 2D: ccRCC. i) Part 1B: solid tumors with KRAS G12C mutation. ii) Part 2B: NSCLC with KRAS G12C mutation. iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.
Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
Participants must have measurable disease per RECIST v1.1.

Reasons someone may not be able to joinExclusion criteria

Untreated central nervous system (CNS) metastases.
Leptomeningeal metastasis (carcinomatous meningitis).
Impaired cardiac function or clinically significant cardiac disease.
For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):. i) History of pneumonitis or interstitial lung disease (ILD). ii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). \- Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

John Theurer Cancer Center at Hackensack University Medical CenterHackensack, New Jersey
Local Institution - 0020Allentown, Pennsylvania
The West Clinic, PLLC dba West Cancer CenterGermantown, Tennessee
Local Institution - 0025Dallas, Texas
Local Institution - 0031Brisbane, Queensland
BC Cancer VancouverVancouver, British Columbia
Local Institution - 0015Montreal, Quebec
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-JésusQuébec, Quebec

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 29, 2026. Always confirm current availability with the study team.

View original record ↗